These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38986873)

  • 21. Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets.
    Ilyushina NA; Seiler JP; Rehg JE; Webster RG; Govorkova EA
    PLoS Pathog; 2010 May; 6(5):e1000933. PubMed ID: 20523902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza viruses.
    Ilyushina NA; Govorkova EA; Gray TE; Bovin NV; Webster RG
    PLoS Pathog; 2008 Apr; 4(4):e1000043. PubMed ID: 18404209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic activity of an RNA polymerase PA-PB1 interaction inhibitor with oseltamivir against human and avian influenza viruses in cell culture and in ovo.
    Bonomini A; Zhang J; Ju H; Zago A; Pacetti M; Tabarrini O; Massari S; Liu X; Mercorelli B; Zhan P; Loregian A
    Antiviral Res; 2024 Oct; 230():105980. PubMed ID: 39117284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.
    Wu Y; Gao F; Qi J; Bi Y; Fu L; Mohan S; Chen Y; Li X; Pinto BM; Vavricka CJ; Tien P; Gao GF
    J Virol; 2016 Dec; 90(23):10693-10700. PubMed ID: 27654293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.
    Takashita E; Meijer A; Lackenby A; Gubareva L; Rebelo-de-Andrade H; Besselaar T; Fry A; Gregory V; Leang SK; Huang W; Lo J; Pereyaslov D; Siqueira MM; Wang D; Mak GC; Zhang W; Daniels RS; Hurt AC; Tashiro M
    Antiviral Res; 2015 May; 117():27-38. PubMed ID: 25721488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.
    Govorkova EA; Leneva IA; Goloubeva OG; Bush K; Webster RG
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2723-32. PubMed ID: 11557461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuraminidase inhibitor susceptibility profile of human influenza viruses during the 2016-2017 influenza season in Mainland China.
    Huang W; Cheng Y; Li X; Tan M; Wei H; Zhao X; Xiao N; Dong J; Wang D
    J Infect Chemother; 2018 Sep; 24(9):729-733. PubMed ID: 29866491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo.
    Yen HL; Ilyushina NA; Salomon R; Hoffmann E; Webster RG; Govorkova EA
    J Virol; 2007 Nov; 81(22):12418-26. PubMed ID: 17855542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Highly pathogenic avian influenza H7N9 viruses with reduced susceptibility to neuraminidase inhibitors showed comparable replication capacity to their sensitive counterparts.
    Tang J; Zhang J; Zhou J; Zhu W; Yang L; Zou S; Wei H; Xin L; Huang W; Li X; Cheng Y; Wang D
    Virol J; 2019 Jul; 16(1):87. PubMed ID: 31266524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.
    Baranovich T; Bahl J; Marathe BM; Culhane M; Stigger-Rosser E; Darnell D; Kaplan BS; Lowe JF; Webby RJ; Govorkova EA
    Antiviral Res; 2015 May; 117():10-9. PubMed ID: 25701593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional neuraminidase inhibitor resistance motifs in avian influenza A(H5Nx) viruses.
    Bialy D; Shelton H
    Antiviral Res; 2020 Oct; 182():104886. PubMed ID: 32750468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses.
    Checkmahomed L; Padey B; Pizzorno A; Terrier O; Rosa-Calatrava M; Abed Y; Baz M; Boivin G
    Viruses; 2020 Oct; 12(10):. PubMed ID: 33049959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring.
    Govorkova EA; Baranovich T; Seiler P; Armstrong J; Burnham A; Guan Y; Peiris M; Webby RJ; Webster RG
    Antiviral Res; 2013 May; 98(2):297-304. PubMed ID: 23458714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza Viruses with PA/I38T or PA/E23K Substitutions in the Ferret Model.
    Koszalka P; George A; Dhanasekaran V; Hurt AC; Subbarao K
    mBio; 2022 Aug; 13(4):e0105622. PubMed ID: 35938724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influenza A virus polymerase acidic protein E23G/K substitutions weaken key baloxavir drug-binding contacts with minimal impact on replication and transmission.
    Jones JC; Zagribelnyy B; Pascua PNQ; Bezrukov DS; Barman S; Okda F; Webby RJ; Ivanenkov YA; Govorkova EA
    PLoS Pathog; 2022 Jul; 18(7):e1010698. PubMed ID: 35830486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.
    Hurt AC; Selleck P; Komadina N; Shaw R; Brown L; Barr IG
    Antiviral Res; 2007 Mar; 73(3):228-31. PubMed ID: 17112602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013.
    Meijer A; Rebelo-de-Andrade H; Correia V; Besselaar T; Drager-Dayal R; Fry A; Gregory V; Gubareva L; Kageyama T; Lackenby A; Lo J; Odagiri T; Pereyaslov D; Siqueira MM; Takashita E; Tashiro M; Wang D; Wong S; Zhang W; Daniels RS; Hurt AC
    Antiviral Res; 2014 Oct; 110():31-41. PubMed ID: 25043638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Susceptibility of avian influenza viruses of the N6 subtype to the neuraminidase inhibitor oseltamivir.
    Stoner TD; Krauss S; Turner JC; Seiler P; Negovetich NJ; Stallknecht DE; Frase S; Govorkova EA; Webster RG
    Antiviral Res; 2012 Mar; 93(3):322-9. PubMed ID: 22252168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.
    Noshi T; Kitano M; Taniguchi K; Yamamoto A; Omoto S; Baba K; Hashimoto T; Ishida K; Kushima Y; Hattori K; Kawai M; Yoshida R; Kobayashi M; Yoshinaga T; Sato A; Okamatsu M; Sakoda Y; Kida H; Shishido T; Naito A
    Antiviral Res; 2018 Dec; 160():109-117. PubMed ID: 30316915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influenza A(H1N1)pdm09 virus exhibiting reduced susceptibility to baloxavir due to a PA E23K substitution detected from a child without baloxavir treatment.
    Takashita E; Abe T; Morita H; Nagata S; Fujisaki S; Miura H; Shirakura M; Kishida N; Nakamura K; Kuwahara T; Mitamura K; Ichikawa M; Yamazaki M; Watanabe S; Hasegawa H;
    Antiviral Res; 2020 Aug; 180():104828. PubMed ID: 32574689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.